Information Provided By: 
Fly News Breaks for January 20, 2017
PFE
Jan 20, 2017 | 06:10 EDT
Pfizer's dividend yield breached the 4% level at yesterday's close for the first time since the U.S. Treasury inversion notice that led to the collapse of the Allergan (AGN) deal in early April 2016, Piper Jaffray analyst Richard Purkiss tells investors in a research note. The analyst thinks value-oriented investors should now take a close look at the company's four-year outlook. Purkiss sees Pfizer posting 9.6% annual earnings growth over the next four years and reiterates an Overweight rating on the shares with a $53 price target.
News For PFE From the Last 2 Days
There are no results for your query PFE
